Evaluation of Combined Live, Attenuated Respiratory Syncytial Virus and Parainfluenza 3 Virus Vaccines in Infants and Young Children
Citations Over TimeTop 10% of 2004 papers
Abstract
We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.
Related Papers
- → Pneumovirus in Dogs with Acute Respiratory Disease(2010)56 cited
- → Paramyxoviruses: Respiratory Syncytial Virus and Human Metapneumovirus(2014)13 cited
- → The Molecular Biology of Human Respiratory Syncytial Virus (RSV) of the Genus Pneumovirus(1991)90 cited
- → Immunization strategies for the prevention of pneumovirus infections(2007)9 cited
- → Pneumovirus and Metapneumovirus: Respiratory Syncytial Virus and Human Metapneumovirus(2010)1 cited